FEPITRIZOL is a hypnotic agent.

Fenalcomine is a coronary vasodilator, cardiotonic and local anesthetic agent. It was studied in the treatment of angina pectoris.

Amiquinsin hydrochloride, 4-amino-6,7-dimethoxquinoline hydrochloride hydrate, is a drug, which exhibits hypotensive activity. Amiquinsin has a more prolonged hypotensive effect than the hydroxyquinoline.

Amphetaminil is chemically an alpha-phenyl-alpha-[(1-methyl-2-phenyl)-ethylamino]-acetonitrile (1), i.e. a derivative of alpha-aminonitrile. It was was developed in the 1970s in Germany and marketed under the brand name Aponeuron. Administration of Aponeuron proved useful in the treatment of children with hyperkinetic syndrome. The subtle and crude motorics improved, symptoms of hyperactivity disappeared and the general school performance of the child improved. Aponeuron was also used in the treatment of disorders of erectile potency, chronic schizophrenia and narcolepsy. In 1974 amphetaminil was included in the class of addictives or habit-forming drugs, although prescription of the drug is not requiring adherence to strict requirements. Nevertheless, it has largely been withdrawn from clinical use.

Revamilast is an orally active, potent and selective phosphodiesterase 4 (PDE 4) inhibitor that is being studied for its potential in treatment of inflammatory disorders. PDE 4 inhibitors attenuate the inflammatory response and suppress many cytokines, including TNF-α production in mononuclear cells. Initial studies showed no serious adverse events in healthy volunteers and phase II studies have evaluated the effect of revamilast on long function and rheumatoid arthritis.

Adozelesin (U 73975, adolezesin) is an experimental antitumor drug of the duocarmycin class. Adozelesin is a highly potent alkylating agent that undergoes binding in the minor groove of double-stranded DNA (ds-DNA) at A-T-rich sequences followed by covalent bonding with N-3 of adenine in preferred sequences. Adozelesin is therapeutically active against a broad spectrum of tumours and was in phase II clinical trials with Pharmacia Corporation (now Pfizer) in the US for breast cancer treatment. Phase I and Phase II clinical trials were conducted in 2000s, however, it was found adozelesin had marginal efficacy in the treatment of metastatic breast cancer at the dosage and schedule used.